Analysis of PTRHD1 common and rare variants in European patients with Parkinson’s disease

1. Introduction

Parkinson’s disease is a complex neurodegenerative disorder resulting from a variety of genetic and non-genetic risk factors. Three family studies nominated peptidyl-tRNA hydrolase domain containing 1 gene (PTRHD1) as a possible disease-causing gene in atypical parkinsonism (Jaberi et al., 2016; Khodadadi et al., 2017; Kuipers et al., 2018). In these studies, two conducted in Iranian families (Jaberi et al., 2016; Khodadadi et al., 2017) and one in a specific sub-Saharan African community (Kuipers et al., 2018), the carriers showed some level of early onset cognitive impairment, and later developed symptoms of parkinsonism. In particular, homozygous PTRHD1 c.157C>T (p.His53Tyr) variants were detected in two Iranian siblings with intellectual disability and motor abnormalities. At their second/third decade of age, the siblings presented with muscle stiffness, anxiety, resting and postural tremor, along with hypersexuality and hypersomnia (Khodadadi et al., 2017). Similar symptoms, including intellectual disability/attention deficits and, successively, gait disturbance, bradykinesia, tremor and falls, have also been reported in two male siblings from another Iranian family, homozygous carriers of a PTRHD1 c.155G>A (p.Cys52Tyr) variant (Jaberi et al., 2016). Likewise, the study on the Sub-Saharan Xhosa-speaking community showed that, within the same family, three homozygous carriers of a PTRHD1 deletion (c.169_196del, p.Ala57Argfs*26) had mental disability and symptoms of parkinsonism, with a wider clinical variability compared to the two previous studies (one member showed just tremor, one just bradykinesia and hypokinesia, one both) (Kuipers et al., 2018).

Despite these findings, no large-scale study has been performed before in the European population to investigate the relationship between PTRHD1 and PD. To test this potential association, we examined the PTRHD1 region in Europeans using whole genome sequencing (WGS) data from the Accelerating Medicines Partnership - Parkinson’s disease initiative (AMP-PD; www.amp-pd.org) and large-scale genome-wide imputed genotyping data from the International Parkinson’s Disease Genomics Consortium (IPDGC).

2. Methods

3. Results

In the WGS data we identified 1829 variants in the PTRHD1 region +/-100 Kb, of which 29 were found within the PTRHD1 gene. Among these, two were coding variants and 13 were identified as rare variants (MAF < 0.01). After Bonferroni correction, both logistic regression and Fisher test showed no association between PTRHD1 variants and PD (Supplementary Tables S1-S2). We repeated the analyses using GWAS individual-level data and detected 511 variants in the PTRHD1 region +/-100 Kb, with 14 variants in PTRHD1 gene, none of which were coding. Similarly, the results showed no significant association between PTRHD1 and PD (Supplementary Tables S3-S4). In addition, the analyses using the PD meta-analysis summary statistics confirmed such lack of association of PTRHD1 with PD risk as well as with PD AAO (Figure 1). Finally, burden and kernel tests in WGS data did not show an enrichment of PTRHD1 rare variants in PD, compared to controls (Supplementary Table S5). As the previously identified PTRHD1 variants were all homozygous, we also assessed the number of homozygous/compound heterozygous carriers of at least one PTRHD1 coding variant, showing similar proportions of such carriers between PD patients and controls (Supplementary Table S6). Of note, the three PTRHD1 variants reported in the previous studies on Iranian and African families (Jaberi et al., 2016; Khodadadi et al., 2017; Kuipers et al., 2018) were not found in our dataset.

• Download figure
• Open in new tab

Fig. 1

(A) Locus zoom plot of PTRHD1 variants versus PD risk. (B) Locus zoom plot of PTRHD1 variants versus PD AAO. The position of the variants on the chromosome 2 (x axis) is plotted against the log10-scaled p-values (left y axis). The most strongly associated SNP is indicated by a purple diamond. Pairwise linkage disequilibrium scores are defined by different colors, explained by the legend on the upper right corner. The right vertical axis indicates the regional recombination rate (cM/Mb).

Abbreviations: chr, chromosome; cM, centimorgan; Mb, Megabase; PD, Parkinson’s disease; SNP, single nucleotide polymorphism.

4. Discussion

Herein, we did not find evidence for an association between PTRHD1 and PD in the European population. There are several reasons that might explain the discrepancy between our results and the previous findings on PTRHD1 in parkinsonian families (Jaberi et al., 2016; Khodadadi et al., 2017; Kuipers et al., 2018): 1) The findings from the family studies might not replicate on a large scale, suggesting that PTRHD1 variants might be either extremely rare in PD or not associated at all; 2) PTRHD1 carriers in the reported family studies manifested atypical parkinsonism with early-onset intellectual impairment, whereas our study was performed on patients with typical PD. Therefore, PTRHD1 variants might be associated with rare forms of atypical parkinsonism, rather than typical PD; 3) The family studies were performed in Iranian and African subjects, whereas our study was performed in European patients. These ethnic differences might as well explain the discrepancy between our and the three previous family studies on PTRHD1. Our findings are further supported by a recent study conducted on PD families and early onset PD patients in a Taiwanese population (Chen et al., 2020). The study demonstrated an absence of PTRHD1 pathogenic coding variants in PD patients.

In conclusion, our results do not provide evidence for an association between PTRHD1 and PD. Larger studies on non-European ancestry populations and family trios are required to clarify the role of PTRHD1 in PD and atypical parkinsonism.

6. Conflicts of Interest

ZGO has received consulting fees from Lysosomal Therapeutics Inc., Idorsia, Prevail Therapeutics, Denali, Ono Therapeutics, Neuron23, Handl Therapeutics, Deerfield and Inception Sciences (now Ventus). None of these companies were involved in any parts of preparing, drafting and publishing this study. Other authors have no additional disclosures to report.